Plain-English translation of NCT03439280 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Read our Multiple myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers tested a medication called TAK-079 to see if it could help people with multiple myeloma that has stopped responding to other treatments. The trial studied how safe the medication was, how well it worked, and how the body processed it. This was an early-stage trial where doctors started with lower doses and gradually increased them to find the right amount.
Multiple myeloma is a serious blood cancer, and some patients' disease stops responding to available treatments, leaving them with few options. This trial investigated whether this medication could offer a new hope for those patients who have run out of other choices.
Participants received injections of the medication under the skin, starting with weekly shots for 8 weeks, then every 2 weeks for 16 weeks, and then monthly. The trial lasted up to 3.5 years total, with participants continuing treatment until the cancer progressed, they experienced unacceptable side effects, or they chose to stop. Doctors monitored participants regularly for how well the medication worked and any side effects it caused.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
United States